98%
921
2 minutes
20
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease that impacts blood glucose levels and can also lead to an increased prevalence of psychiatric conditions. Living with T1DM has been associated with a significant impact on a person's social, mental, and psychological quality of life (QoL). Stressors related to T1DM include the demands of managing the condition, acceptance of the diagnosis, and recognition of the sizeable personal responsibility involved in managing the condition. Participating in treatment designed to improve QoL can still take a psychological toll on individuals with T1DM and can lead to a wide range of psychological distress, including anxiety, fear, depression, stress, anger, frustration, and denial (among many others). Ongoing research seeks to investigate the range of psychiatric conditions that are common among people with T1DM. Bringing patient perspectives into research to design and implement workable solutions is the future of a novel holistic approach to managing T1DM-related mental health impact. Connecting with other people living with T1DM, clinicians, counselors/therapists, mental health professionals, and social workers might alleviate some of the challenges of managing the emotional issues and psychological distress associated with T1DM. Here, we provide the perspective of someone with over 33 years of living with T1DM, its impact on his mental health, QoL, the steps undertaken, and the path to successful management. This perspective is complemented by opinions from two expert clinicians-an endocrinologist and a psychiatrist. Sharing the real-life subjective burden experienced by the person living with diabetes could be one step towards increasing awareness of the toll of mental health disorders on people living with T1DM. This patient experience, complemented by expert endocrinologist and psychiatrist opinions, could pave the way for an effective two-way dialogue to manage the condition effectively.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10838889 | PMC |
http://dx.doi.org/10.1007/s13300-023-01527-w | DOI Listing |
Diabetes Obes Metab
September 2025
Allam Diabetes Centre, University of Hull, Hull, UK.
Introduction: Diabetes is the leading cause of end-stage renal disease (ESRD) in the United Kingdom, accounting for one third of individuals starting renal replacement therapy (RRT). Data on the prevalence of diabetes distress (DD) in people with Diabetic Kidney Disease (DKD) on dialysis are scarce.
Aim: To describe the prevalence of DD in people living with diabetes undergoing haemodialysis.
Br J Hosp Med (Lond)
August 2025
Department of Thyroid Surgery, Center of Breast Disease Diagnosis and Treatment, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Severe heart failure (SHF) secondary to chronic kidney disease (CKD) in type 1/2 diabetes mellitus (T1/T2DM) patients presents a critical global health challenge. Leveraging data from the Global Burden of Disease (GBD) 2021, we analyse epidemiological trends (1990-2021) and project disease trajectories to 2040, focusing on sociodemographic disparities and metabolic determinants. Utilising GBD 2021 data, the estimated prevalence and years lived with disability (YLDs) values were extracted for SHF-CKD-T1/T2DM, along with their corresponding 95% uncertainty intervals (UIs).
View Article and Find Full Text PDFJ Diabetes
August 2025
Cellular and Molecular Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disorder where the immune system targets and destroys insulin-producing β-cells in the pancreas. It generally emerges during childhood or adolescence, but individuals of any age can be affected. In contrast to Type 2 diabetes mellitus (T2DM) which is often associated with lifestyle factors, T1DM cannot be prevented and necessitates lifelong management.
View Article and Find Full Text PDFInt J Environ Res Public Health
June 2025
Centre Hospitalier de Cayenne, Cayenne 97306, French Guiana.
This study aimed to determine the prevalence of type 1 diabetes mellitus (T1DM) in French Guiana and describe the social profiles of the patients. We conducted a multicenter cross-sectional study of children under 18 years who were diagnosed with type 1 diabetes and followed up from 2002 to 2021. Over a 20-year period, 48 children under 18 years with type 1 diabetes living in French Guiana were included in the study, out of a total of 59 cases.
View Article and Find Full Text PDFJMIR Diabetes
July 2025
National Institute for Health and Care Research HealthTech Research Centre, Sheffield Children's NHS Foundation Trust, Sheffield, United Kingdom.
Background: Transition to adult health care for young people and young adults (YP/YA) with type 1 diabetes mellitus (T1DM) starts around 11 years of age, but transition services may not meet their needs. A combination of self-management support digital health technologies exists, but no supportive chatbots with components to help YP/YA with T1DM were identified.
Objective: The aims of this study were to (1) evaluate the novel DigiBete Chatbot, the first user-led, developmentally appropriate, clinically approved transition chatbot for YP/YA with T1DM from four English diabetes services and (2) assess the feasibility of a future trial of the chatbot.